German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL – Research Report). The ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease ...

UnitedHealth Group provided a 2025 profit forecast below Wall Street estimates on Tuesday as it expects pressure across its ...

Investors can either buy these names or call options on them.

The brand evolution will see Midwich Ltd (including Holdan, Invision, PSCo, Pulse Cinemas, and Square One), Midwich APAC, ...